FibroGen
Mairead Carney has extensive experience in clinical operations and development, currently serving as Senior Director of Clinical Operations at FibroGen, Inc. since April 2011, where oversight includes early phase clinical development programs in oncology, liver fibrosis, and muscular dystrophy. Prior roles at FibroGen include Director and Associate Director of Clinical Development, as well as Clinical Program Manager for critical Phase 1 and Phase 2 clinical trials. Earlier experience includes a position as Clinical Trial Manager at SciClone Pharmaceuticals and as a Senior Clinical Research Associate at Forest Laboratories, highlighting a solid foundation in clinical trial management. Mairead holds a Bachelor of Arts degree in Biology from Colby College, obtained in 2002.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.